Clinical Observation On The Treatment Of Chronic Obstructive Pulmonary Disease In Stable Stage With Buyiwith Buyi Pishen Huatan Tongluo Decoction

Objective:Treatment of COPD patients in stable stage(lung,spleen and kidney qi deficiency,phlegm and blood stasis syndrome)with Buyi Pishen Huatan Tongluo decoction.The purpose is to observe the clinical effect of this prescription,so as to provide a theoretical basis for the treatment of COPD in the future.Methods:This study collected 64 patients with stable chronic obstructive pulmonary disease(lung,spleen and kidney qi deficiency,phlegm and blood stasis syndrome)from September 2020 to December 2021 in the Department of Respiratory Medicine,Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine.There were 32 cases in each treatment group.The control group was treated with tiotropium bromide powder spray.on this basis,the treatment group was treated with Buqi Tongluo Xingqi Huatan Decoction.The observation time of both groups was 3months.The changes of clinical symptoms,inflammatory factors,lung function,T lymphocytes,CAT score and 6MWD were observed before and after intervention.Results:1.In terms of the basic situation:Before intervention,comparing the age,sex,course of disease,TCM symptoms scores,inflammatory factor,lung function,T Lymphocyte immune function function,CAT scores,6-minu te walking distance of the two groups of patients,those difference wa s not statistically significant(P>0.05).2.In terms of TCM main symptom score:The main symptoms of the co ntrol group and the treatment group were significantly improved after intervention(P<0.05),And the main symptoms of the treatment group im proved significantly after the intervention(P<0.05),In terms of TCM secondary symptom score:after the intervention,the symptoms of chest tightness,shortness of breath and fatigue in the control group weres ignificantly improved compared with those before the intervention(P<0.05),but the symptoms of less food,perspiring,bad wind,abdominal d istension,loose stool,soft,dizziness,tinnitus,nocturia,chest pain,pur ple dark tongue and greasy moss were not improved(P>0.05),After the intervention,all secondary symptoms in the treatment group were impro ved(P<0.05),Compared with the control group,the secondary symptom s cores of the treatment group after the intervention were improved mor e significantly(P<0.05),In terms of the total score of TCM symptoms:the control group and the treatment group improved after the interven tion(P<0.05),and the treatment group improved more significantly af ter the intervention(P<0.05).3.In terms of inflammatory indicators:After intervention,Neutrophi l(N)and C-creative protein(CRP)in the control group and the treatment group did not significantly decrease(P>0.05),the N and CRP of the two groups was no significant difference after intervention(P>0.05).4.In terms of pulmonary function: The first second forced expiratory volume(FEV1),forced vital capacity(FVC)and one second rate(FEV1 /FVC)in the control group after intervention were not increased(P>0.05),the FEV1,FVC,FEV1/FVC in the treatment group after intervention were increa sed(P<0.05),the FEV1,FVC and FEV1/FVC of the two groups was no ingifi cant difference after intervention(P>0.05).5.In terms of CAT score:The CAT value of the control group and the treatment group decreased after the intervention(P<0.05),and the CAT value of the treatment group decreased more significantly after the intervention(P<0.05).6.In terms of 6MWD: The 6MWD of the control group and the treatment group increased after the intervention(P<0.05),and the 6MWD of the treatment group increased more significantly after the intervention(P<0.05).7.In terms of T lymphocyte immune function:The CD3 and CD4 of the control group were not significantly increased(P>0.05),and CD8 did not decrease(P > 0.05),the CD3 and CD4 of the treatment group were significantly increased(P<0.05),and the CD8 was significantly decreased(P<0.05),Compared with the control group,the CD3 and CD4 in the treatment group increased significantly(P<0.05),and CD8 decreased significantly(P<0.05).8.In terms of clinical efficacy:the total effective rate was 73.33%in the control group,and 86.66% in the treatment group.The total effective rate of the treatment group was better than that of the control group(P<0.05).9.During the whole clinical research process,there were no adverse events in the control group and the treatment group,which indicated that Buqi Tongluo Xingqi Huatan Decoction had certain safety.Conclusion:Buyi Pishen Huatan Tongluo Decoction can significantly alleviate the clinical symptoms of patients with stable COPD(Qi deficiency,phlegm and blood stasis syndrome),enhance the immune function,improve exercise endurance and improve the quality of life.However,the effect of inhibiting inflammation and improving lung function is not obvious,which needs further research.